ADPT Adaptive Biotechnologies Corp

P/E --
Forward P/E --
Price/Sales 10.09
Beta 2.151
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 ADPT surges 5.1% today fueled by business separation plans and recent convertible notes offering

ADPT is trading 5.1% up at $20.33 today. • This follows the company's recent announcement on June 15, 2026, of its plan to separate the Minimal Residual...

🟢 ADPT makes sharp 10.5% jump

ADPT is trading at $19.04, up 10.5% versus the comparison close of $17.23 during regular trading. This is a price-movement alert; no separate company-specific...

🟢 ADPT extends move to 6.9% up

ADPT is trading at $18.42, up 6.9% versus the comparison close of $17.23 during regular trading. This is a price-movement alert; no separate company-specific...

🟢 ADPT is trading 5% up today, rebounding from recent financing-related weakness

ADPT is trading about 5% up today at $18.09, rebounding from recent weakness despite no fresh company-specific headlines this morning. • The move appears...

Adaptive Biotechnologies Closes $345M Convertible Note Offering, Repays OrbiMed Agreement

Adaptive Biotechnologies Closes $345M Convertible Note Offering, Repays OrbiMed Agreement

Adaptive Biotechnologies announced the issuance of $345 million in 0% Convertible Senior Notes due 2031, including the full exercise of a $45 million option by...

🔴 Adaptive Biotechnologies Corp is trading 4.3% down today on dilution concerns from $300M convertible notes and restructuring

Adaptive Biotechnologies Corp is trading 4.3% down at $16.48 today as investors weigh the impact of an upsized $300 million convertible notes offering and a...

🟢 Adaptive Biotechnologies Corp is trading 4.8% up today as it rebounds from a sharp drop following restructuring and upsized financing news

• The company announced a strategic split between its MRD cancer-testing diagnostics business and its Immune Medicine drug-discovery arm to optimize its...

🔴 Adaptive Biotechnologies Corp is trading 4.4% down today on business split and $250M convertible notes offering

Adaptive Biotechnologies Corp is trading 4.4% down at $16.69 today after announcing a major business restructuring and a $250 million private financing...

Adaptive Biotechnologies Splits in Two and Borrows $250 Million — Is This a Cleanup or a Fire Sale?

Adaptive Biotechnologies Splits in Two and Borrows $250 Million — Is This a Cleanup or a Fire Sale?

Shares of Adaptive Biotechnologies sank 7.2% to $16.20 in pre-market trading after the company unveiled a double-barreled announcement late Sunday: it will...

🔴 Adaptive Biotechnologies Corp is trading 7.2% down today after business separation and $250M convertible notes offering

Adaptive Biotechnologies Corp is trading 7.2% down at $16.20 in pre-market trading after announcing a strategic business separation and a $250 million...

Adaptive Biotechnologies Announces Business Separation and $250M Convertible Notes Offering

Adaptive Biotechnologies announced a plan to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to allow each segment to pursue...

🔴 Adaptive Biotechnologies Corp is down 9.5% today following Convertible Senior Notes Offering and Plan to Separate Businesses

Adaptive Biotechnologies Corp. is trading 9.5% down at $15.81 in after-hours trading after announcing a proposed offering of $250 million in convertible senior...

🔴 Adaptive Biotechnologies Corp extends move to 5.0% down

ADPT is trading at $17.79, down 5.0% versus the comparison close of $18.73 during regular trading. This is a price-movement alert; no separate company-specific...

🔴 Adaptive Biotechnologies Corp is trading 4.2% down today on profit-taking after a multi-day rally on positive clonoSEQ data

Adaptive Biotechnologies Corp is trading at $17.95, down 4.2% today as the stock undergoes consolidation following a significant multi-day rally. • The recent...

🟢 Adaptive Biotechnologies Corp is trading 6.7% up today, rallying on positive clinical data and outlook

Adaptive Biotechnologies Corp is trading 6.7% higher at $19.99 in pre-market, extending a rally driven by positive company developments. • The surge follows...